Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $11.42.

A number of research firms have recently commented on HCAT. Stephens lowered their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research report on Friday. Piper Sandler dropped their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. JPMorgan Chase & Co. increased their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Finally, Evercore ISI reduced their price target on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th.

Health Catalyst Stock Up 0.9 %

Shares of HCAT stock opened at $7.70 on Friday. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.41. The company’s fifty day simple moving average is $7.43 and its 200-day simple moving average is $6.90. The firm has a market cap of $454.57 million, a PE ratio of -4.16 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The business had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. During the same period in the previous year, the company earned ($0.21) earnings per share. The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, equities analysts predict that Health Catalyst will post -0.35 earnings per share for the current fiscal year.

Insider Activity at Health Catalyst

In related news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares of the company’s stock, valued at approximately $1,062,018.64. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,153 shares of company stock valued at $216,004. Insiders own 2.70% of the company’s stock.

Institutional Trading of Health Catalyst

Several institutional investors and hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. grew its holdings in Health Catalyst by 6.9% during the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after buying an additional 1,907 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Health Catalyst by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after buying an additional 2,164 shares in the last quarter. Quarry LP grew its position in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after acquiring an additional 2,610 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Health Catalyst by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock valued at $375,000 after purchasing an additional 2,831 shares during the last quarter. Finally, ClariVest Asset Management LLC raised its holdings in Health Catalyst by 1.2% during the 2nd quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock valued at $1,825,000 after buying an additional 3,302 shares during the period. 85.00% of the stock is currently owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.